Perampanel may reduce alpha-synuclein transmission in Parkinson's disease. A possible therapeutic target?

Dr. Michele Matarazzo speaks with Prof. Ryosuke Takahashi about the results of his recent study that shows how this anti-epileptic drug may inhibit the transmission of alpha synuclein in PD. While this was tested in animal models, future clinical trials are warranted to test the effects on PD progression. Read the article